On March 14, 2025, the Ifakara Health Institute welcomed representatives from the Global Health Clinical Trials Consortium (GHCC) to its Bagamoyo branch. The visit served as a platform for discussions on Ifakara’s contributions to clinical trials, research methodologies, and opportunities for collaboration to advance global health research.

GHCC, an initiative backed by the Gates Foundation, unites ten Product Development Partners (PDPs) dedicated to improving the efficiency of clinical trials worldwide. Collectively, these PDPs oversee 60 to 120 ongoing and planned trials at any given time, leveraging shared expertise and resources to accelerate the development of life-saving health interventions.

A tour of cutting-edge research facilities

During their visit, GHCC representatives toured Ifakara’s state-of-the-art facilities, including its advanced laboratory, Clinical Trials Facility, and the Vector Control Product Testing Unit. These facilities play a critical role in the institute’s mission to develop and evaluate innovative health solutions.

Strengthening global partnerships in clinical research

The engagement underscored the importance of collaboration and knowledge-sharing in driving impactful clinical research. Discussions focused on enhancing trial efficiency, refining study methodologies, and expanding strategic partnerships to foster innovation in global health.

About Ifakara’s Clinical Trials Facility

Located on the outskirts of Bagamoyo, Kingani Clinical Trials Facility (CTF), widely known by the name of ‘Kingani Hospital,’ has a track record in designing and conducting Phase I to Phase III GCP-compliant clinical studies, as well as analysis and reporting for regulatory review and licensure. The site is supported by an institutional quality assurance team.

IHI uses the CTF to conduct high quality clinical trials in close collaboration with national and international institutions and organizations including: Muhimbili National Hospital, National Institute for Medical Research (NIMR), Swiss Tropical and Public Health Institute (Swiss TPH), University of Lausanne, Medicines for Malaria Venture, Malaria Vaccine Initiative, European Vaccine Initiative, Novartis, GSK, and Sanaria Inc (USA).